We are live on ! Find out more

312 hedge funds and large institutions have $3.87B invested in ResMed in 2014 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 93 increasing their positions, 130 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding in top 10

Funds holding in top 10: 25 (+3)

12% more call options, than puts

Call options by funds: $30.8M | Put options by funds: $27.5M

8% more capital invested

Capital invested by funds: $3.58B → $3.87B (+$291M)

6% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 31

2% less funds holding

Funds holding: 318312 (-6)

2.12% less ownership

Funds ownership: 56.63%54.51% (-2.1%)

28% less repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 130

Holders
312
Holders Change
-6
Holders Change %
-1.89%
% of All Funds
8.97%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.14%
New
29
Increased
93
Reduced
130
Closed
31
Calls
$30.8M
Puts
$27.5M
Net Calls
+$3.33M
Net Calls Change
+$65.7M

RMD Hedge Fund Activity: Q2 2014 in Review

312 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q2 2014, worth a combined $3.87B — up 8.1% from $3.58B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of RMD and 29 opened new positions — a net loss of 2 holders — while 130 trimmed existing stakes and 93 added.

The largest buyer was Macquarie Group, adding an estimated $71.6M. The largest seller was Bank of New York Mellon, cutting an estimated $41.8M.

  • 312 institutional investors held ResMed (RMD) as of Q2 2014, down from 318 in Q1 2014.
  • Funds reported $3.87B of ResMed stock for Q2 2014, up 8.1% quarter-over-quarter.
  • 29 funds opened new ResMed positions in Q2 2014 and 31 closed out, a net change of -2 holders.
  • The largest ResMed buyer in Q2 2014 was Macquarie Group, an estimated $71.6M added.
  • The largest ResMed seller in Q2 2014 was Bank of New York Mellon, an estimated $41.8M sold.

Based on aggregated 13F filings for Q2 2014.